NCT04692077View on ClinicalTrials.gov

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

July 7, 2023

Study Completion Date

July 7, 2023

Conditions
HIV Infections
Interventions
DRUG

Cabotegravir (CAB) tablet

30 mg tablets

DRUG

CAB LA

Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter.

DRUG

Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet

300 mg/200 mg fixed-dose combination tablets

Trial Locations (4)

38105

St. Jude Children's Research Hosp. ATN CRS, Memphis

60612

John H. Stroger Jr. Hosp. of Cook County ATN CRS, Chicago

80045

University of Colorado Denver ATN CRS, Aurora

02215

The Fenway Institute ATN CRS, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04692077 - Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males | Biotech Hunter | Biotech Hunter